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Purpose: To assess the relationship between serum insulin-like growth factor I (IGF-I) and diabetic retinopathy.
Methods: This was a clinic-based cross-sectional study conducted at the Emory Eye Center. A total of 225 subjects were
classified into four groups, based on diabetes status and retinopathy findings: no diabetes mellitus (no DM; n=99), diabetes
with no background diabetic retinopathy (no BDR; n=42), nonproliferative diabetic retinopathy (NPDR; n=41), and
proliferative diabetic retinopathy (PDR; n=43). Key exclusion criteria included type 1 diabetes and disorders that affect
serum IGF-I levels, such as acromegaly. Subjects underwent dilated fundoscopic examination and were tested for
hemoglobin A1c, serum creatinine, and serum IGF-I, between December 2009 and March 2010. Serum IGF-I levels were
measured using an immunoassay that was calibrated against an international standard.
Results: Between the groups, there were no statistical differences with regards to age, race, or sex. Overall, diabetic
subjects had similar serum IGF-I concentrations compared to nondiabetic subjects (117.6 µg/l versus 122.0 µg/l; p=0.497).
There was no significant difference between serum IGF-I levels among the study groups (no DM=122.0 µg/l, no
BDR=115.4  µg/l,  NPDR=118.3  µg/l,  PDR=119.1  µg/l;  p=0.897).  Among  the  diabetic  groups,  the  mean  IGF-I
concentration was similar between insulin-dependent and non-insulin-dependent subjects (116.8 µg/l versus 118.2 µg/l;
p=0.876). The univariate analysis of the IGF-I levels demonstrated statistical significance in regard to age (p=0.002,
r=-0.20), body mass index (p=0.008, r=−0.18), and race (p=0.040).
Conclusions: There was no association between serum IGF-I concentrations and diabetic retinopathy in this large cross-
sectional study.
Diabetes mellitus continues to be a tremendous health
burden throughout the world. The molecular pathophysiology
of diabetic retinopathy, which remains the leading cause of
blindness in Americans aged 20 to 74 years of age, is complex
and  involves  multiple  mechanisms  [1].  Retinal
neovascularization  is  a  major  cause  of  sight-threatening
complications in diabetic patients, and the mechanism of its
development  is  not  completely  understood.  Experimental
studies  performed  over  40  years  ago  demonstrated  that
pituitary ablation resulted in remission of diabetic retinopathy,
possibly  because  of  reduced  circulating  levels  of  growth
hormone [2–4]. However, additional studies led investigators
to suggest that a reduction in secondary growth factors, such
as insulin-like growth factor-I (IGF-I), caused the remission
of retinopathy [5,6].
IGF-I, or somatomedin C, is homologous to proinsulin,
and is the major mediator of the growth-promoting effects of
growth  hormone  [7].  While  experimental  and  clinical
evidence suggests that serum IGF-I concentrations may be
involved  in  the  development  of  diabetic  retinopathy,  the
relationship  is  still  controversial.  Several  studies  have
reported that higher serum IGF-I levels may be a risk factor
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for  the  development  of  severe  diabetic  retinopathy  [7–9].
Conversely, a few studies have shown no association between
serum IGF-I levels and the development or progression of
diabetic  retinopathy  [10–13].  It  is  possible  that  this
disagreement stems from the various assays used to measure
IGF-I levels. The purpose of this study was to assess the
relationship  between  serum  IGF-I  levels  and  diabetic
retinopathy, using a novel immunoassay calibrated to the new
World Health Organization standard.
METHODS
Study  design:  The  Emory  University  Institutional  Review
Board  approved  this  study,  which  was  conducted  in
accordance  with  the  Health  Insurance  Portability  and
Accountability  Act  regulations.  A  clinic-based  cross-
sectional study was designed at the Emory Eye Center, and all
patients were enrolled between December 16, 2009 and March
21, 2010. Patients who were seen in the retina, glaucoma,
cornea, and comprehensive ophthalmology clinics during the
enrollment period were considered potential study subjects.
These patients were screened by the study investigators to
determine  their  age,  race,  sex,  and  diabetes  status.  After
undergoing routine ophthalmic examination, which included
dilated fundoscopy, subjects were recruited for inclusion in
the four study groups. Attempts were made to keep the study
groups equally matched according to age, race, and sex.
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2318Study  subjects:  Subjects  were  divided  into  four  distinct
groups,  based  on  their  diabetes  status  and  retinopathy
findings.  The  first  group  consisted  of  subjects  without
diabetes. Subjects in this group were not excluded if they had
other  forms  of  ocular  disease,  such  as  uveitis  or  macular
degeneration. The no background diabetic retinopathy (no
BDR) group consisted of subjects with type 2 diabetes but no
evidence of diabetic retinopathy, such as microaneurysms,
cotton-wool  spots,  intraretinal  hemorrhages,  or  macular
edema. Subjects in the nonproliferative diabetic retinopathy
(NPDR)  group  had  evidence  of  retinopathy,  such  as
microaneurysms,  cotton-wool  spots,  intraretinal
hemorrhages, or macular edema, but no evidence of retinal or
iris neovascularization. The proliferative diabetic retinopathy
(PDR) group consisted of subjects with neovascularization on
the  optic  disc,  retina,  or  iris,  with  or  without  vitreous
hemorrhage or prior panretinal photocoagulation. When the
diabetic retinopathy was asymmetric, the subject was assigned
to  the  group  corresponding  to  the  eye  with  the  worse
retinopathy findings.
Subjects were excluded if they had type 1 diabetes, were
younger than 18, or were older than 90 years of age. Subjects
with prior diseases that suggested baseline alterations in IGF-
I levels, such as acromegaly, were also excluded. Patients who
were  cognitively  impaired  or  unable  to  provide  written
informed consent were excluded as well.
Biochemical  measurements:  Once  enrolled  in  the  study,
subjects completed a medical history questionnaire and had
their blood drawn. Patients were not required to be fasting for
this blood draw. One blood sample was immediately tested
for hemoglobin A1c. Other whole blood, serum, and plasma
samples were frozen at −80 °C. Serum samples were later
tested for creatinine (Beckman Coulter, Inc.; Brea, CA), 25-
hydroxyvitamin D (Immunodiagnostic Systems; Scottsdale,
AZ),  and  IGF-I  levels  (Immunodiagnostic  Systems;
Scottsdale,  AZ).  The  results  of  the  25-hydroxyvitamin  D
testing were reported separately (data not shown).
The  serum  creatinine  was  assayed  using  high-
performance  liquid  chromatography,  which  had  been
standardized  using  isotope  dilution  mass  spectroscopy.
Hemoglobin  A1c  levels  were  also  measured  using  high-
Figure 1. Age-adjusted reference ranges
for  the  IDS  iSYS  insulin-like  growth
factor  (IGF)-I  assay.  For  both  males
(A) and females (B), there is a peak in
serum IGF-I levels during puberty and a
gradual decline during adulthood.
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2319performance liquid chromatography. The serum IGF-I levels
were  measured  from  serum  samples  using  an  automated
competitive  immunoassay  that  was  calibrated  to  the  new
World  Health  Organization  standard.  This  assay  does  not
cross-react with insulin, proinsulin, or IGF-II, and shows no
interference with the high-affinity insulin-like growth factor
binding  proteins  [14].  Figure  1  shows  the  sex-  and  age-
adjusted  normal  data  for  this  assay  [15].  The  Emory
University laboratory is certified by the Clinical Laboratory
Improvement Amendments (CLIA).
Statistical  analysis:  Data  collected  in  the  medical  history
questionnaire included demographic variables such as age,
sex, height, weight, and race (self-assigned as white, black, or
Asian).  The  presence  of  hypertension  or  macrovascular
disease was also recorded. Subjects were considered to have
macrovascular disease if they had ever been diagnosed with a
myocardial infarction or a cerebrovascular accident, or if they
had undergone coronary artery-bypass grafting surgery or a
cardiac  stenting  procedure.  Additionally,  the  duration  of
diabetes (defined as the interval between a subject’s diagnosis
of type 2 diabetes and the time of enrollment in this study) and
insulin usage were recorded for each diabetic patient. The
estimated  glomerular  filtration  rate  (GFR)  was  calculated
according  to  the  Modification  of  Diet  in  Renal  Disease
formula [16].
The means and percentages for patient characteristics
were compared across study groups using one-way ANOVA
and  the  χ2  test,  respectively.  Comparisons  of  mean  IGF-I
levels were made across categorical patient characteristics
using  one-way  ANOVA  and  two  sample  t-tests.  For
comparing the mean IGF-I across race, the six Asian patients
were excluded because of the small sample size. Correlation
coefficients  were  calculated  to  determine  associations
between  IGF-I  concentrations  and  continuous  patient
characteristics. Tukey’s multiple comparison procedure was
used to test pairwise comparisons of patient characteristics
that were significantly different across groups and to test
pairwise comparisons of mean IGF-I concentrations that were
significantly  different  across  patient  characteristics.
Statistical  calculations  were  performed  using  statistical
analysis system (SAS version 9.2; Cary, NC), and statistical
significance was set at a two sided p value of 0.05.
RESULTS
Subject  characteristics:  Table  1  shows  the  clinical
characteristics  of  the  four  study  groups.  There  was  no
statistical difference between the groups with regard to age,
race,  or  sex.  The  mean  body  mass  index  (BMI)  was
statistically lower for the no DM group than the PDR group.
Additionally, the mean hemoglobin A1c was significantly
lower in the no DM group than in the other three groups. The
mean serum creatinine was significantly lower in the no DM
and no BDR groups, compared to the NPDR and PDR groups.
The mean estimated GFR was significantly higher in the no
DM and no BDR groups, compared to the NPDR and PDR
groups.  The  percentage  of  subjects  with  macrovascular
disease was significantly lower in the no DM group, compared
to  the  NPDR  and  PDR  groups.  The  percentage  with
hypertension was statistically lower in the no DM and no BDR
groups, compared to the NPDR and PDR groups.
Insulin-like growth factor I analysis: Diabetic subjects had a
similar  mean  serum  IGF-I  concentration  compared  to
nondiabetic subjects (117.6±52 µg/l versus 122.0±44 µg/l;
p=0.497).  The  mean  serum  IGF-I  concentrations  for  the
groups  were  as  follows:  no  DM=122.0±44  µg/l,  no
BDR=115.4±50  µg/l,  NPDR=118.3±58  µg/l,
PDR=119.1±48 µg/l. There was no significant difference in
mean serum IGF-I levels among the study groups (p=0.897;
Figure 2). Among the diabetic groups, the mean serum IGF-I
concentration was similar among insulin-dependent and non-
insulin-dependent  subjects  (116.8±47  µg/l  versus
118.2±55 µg/l; p=0.876).
TABLE 1. CLINICAL CHARACTERISTICS OF THE FOUR STUDY GROUPS.
Clinical characteristic No DM (n=99) No BDR (n=42) NPDR (n=41) PDR (n=43) p-value
Age (years)* 61.5±12.6 62.4±11.2 68.4±9.9 59.8±11.8 0.708
Race: Black 48 (49%) 21 (50%) 22 (54%) 23 (54%) 0.964
White 49 (49%) 19 (45%) 18 (44%) 19 (44%)  
Asian 2 (2%) 2 (5%) 1 (2%) 1 (2%)  
Sex: Male 49 (49%) 22 (52%) 22 (54%) 22 (51%) 0.971
Body Mass Index* (kg/m2) 28.4±7.1 31.7±9.6 31.3±6.6 33.0±6.7 <0.001
Duration of Diabetes (years)* - 7.5±7.7 19.2±11.1 22.2±10.5 <0.001
Hemoglobin A1c* 5.8±0.4 7.5±1.9 7.4±1.2 8.1±1.8 <0.001
Insulin Usage - 10 (24%) 30 (73%) 31 (72%) <0.001
Macrovascular Disease 13 (13%) 6 (14%) 14 (33%) 19 (44%) <0.001
Hypertension 56 (57%) 28 (67%) 39 (95%) 40 (93%) <0.001
Serum Creatinine* (mg/dl) 0.99±0.64 0.92±0.28 1.90±1.85 2.50±2.78 <0.001
Estimated GFR* (ml/min/1.73m2) 82.22±24.01 89.00±29.76 58.32±31.78 47.70±29.87 <0.001
        *Values indicate the mean±standard deviation. Abbreviations: DM represents diabetes mellitus, BDR represents background
        diabetic retinopathy, NPDR represents non-proliferative diabetic retinopathy, GFR represents glomerular filtration rate.
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2320There was no statistically significant difference in mean
serum  IGF-I  concentrations  according  to  sex  (p=0.174),
macrovascular disease (p=0.375), or hypertension (p=0.131).
Additionally, there was no statistically significant association
between  IGF-I  levels  and  hemoglobin  A1c  (p=0.430,  r=
−0.05), serum creatinine (p=0.181, r=0.09), or estimated GFR
(p=0.369, r=−0.06). While not significantly different, there
was a trend toward decreasing serum IGF-I concentrations
with increasing duration of diabetes (p=0.111, r=-0.14). There
was a statistically significant association between IGF-I and
age (p=0.002, r=−0.20), and between IGF-I and body mass
index (p=0.008, r=−0.18). Figure 3 shows that IGF-I levels
gradually  declined  with  increasing  age.  There  was  a
significant difference in mean IGF-I concentrations between
racial groups (p=0.040). In a subanalysis of race, from which
Asian subjects were excluded, black subjects had higher IGF-
I  levels  than  did  white  subjects  (126.9±47  µg/l  versus
112.9±49 µg/l; p=0.03).
Figure  2.  Serum  insulin-like  growth
factor  (IGF)-I  concentrations  for
individual  patients.  Between  the  four
study groups, there was no significant
difference  in  serum  IGF-I  levels
(p=0.897). The numerical value listed
for  each  group  represents  the  mean
serum IGF-I concentration.
Figure  3.  Serum  insulin-like  growth
factor (IGF)-I concentration in relation
to age. When all study subjects were
considered,  there  was  a  statistically
significant inverse correlation between
serum IGF-I concentration and age.
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The purpose of this cross-sectional study was to assess the
relationship  between  serum  IGF-I  levels  and  diabetic
retinopathy using a novel immunoassay that was calibrated
against  an  international  standard.  This  study  found  no
association  between  serum  IGF-I  levels  and  diabetic
retinopathy. Additionally, there were no differences in serum
IGF-I levels among insulin-dependent diabetic subjects and
non-insulin-dependent  subjects.  Congruent  with  other
studies, serum IGF-I levels were statistically lower in older
subjects.
The role that IGF-I plays in diabetic retinopathy remains
somewhat controversial. Poulsen first suggested a possible
relationship between growth hormone or IGF-I and diabetic
retinopathy  after  he  noted  the  regression  of  proliferative
diabetic retinopathy following pituitary infarction [17]. This
relationship was further supported after experimental studies
showed that pituitary ablation resulted in the regression of
diabetic  retinopathy  [2–4].  Merimee  found  that  growth
hormone-deficient  dwarfs  with  diabetes  exhibited  no
microvascular  complications  [18],  and  later  showed  that
serum IGF-I levels in adult diabetic patients with rapidly
progressive retinopathy were twice those of patients without
retinopathy, of patients with less severe retinopathy, and of
nondiabetic control patients [7]. Later clinical studies by Sato
et al. and Dills et al. also found higher levels of serum IGF-I
in patients with PDR [8,9]. Interestingly, this study showed
no correlation between diabetic retinopathy and serum IGF-I
levels. The variation between these studies’ findings may be
a result of the assays used to measure IGF-I levels.
The  advances  in  IGF-I  assay  methodology  is  critical
when  considering  the  accuracy  of  previous  trials.  Most
modern IGF-I assays have a low cross-reactivity for IGF-II
and binding proteins [19]. However, the problems of many of
the assays include a lack of age-adjusted normal data, lack of
standardization, interference from binding proteins, and lack
of  a  pure  international  reference  population  [19].  These
problems have been minimized by the IDS iSYS assay, which
is a robust IGF-I assay that has been calibrated against a pure
international standard and age-adjusted normative data [14].
Furthermore,  the  assay  does  not  cross-react  with  either
insulin, pro-insulin, or IGF-II, and shows no interference from
the IGF-binding proteins. This assay provides a sensitive and
specific interpretation of serum IGF-I, which is a strength of
the current study.
While this study found no association between serum
IGF-I levels and diabetic retinopathy, it is still possible that
local  IGF-I  plays  a  role  in  the  development  of  diabetic
retinopathy. Experimental evidence suggests that increased
the intraocular concentration and activity of IGF-I may be
responsible for microvascular changes in diabetic retinopathy.
Several studies have shown that elevated intraocular levels of
IGF-I, IGF-II, and IGF-binding protein-3 correlate with the
degree  of  retinal  ischemia  in  diabetic  patients  [20,21].
Spranger et al. [22] also showed that intravitreal levels of IGF-
I were elevated in patients with PDR and that this elevation
correlated  with  plasma  levels.  They  suggested  that  the
increased intraocular IGF-I concentrations were a result of the
spillover  of  serum  protein,  but  could  not  rule  out  the
possibility of local production. Furthermore, they showed that
retinal photocoagulation did not influence intraocular levels
of  IGF-I  [23].  Guidry  and  colleagues  [24]  showed  that
vitreous  fluid  from  patients  with  diabetic  retinopathy
possessed an increased capacity to stimulate the tractional
force  generated  by  Muller  cells  because  of  the  increased
activity of IGF-I, IGF-II, and platelet-derived growth factor.
In another study, Simo et al. [25] found that both vascular
endothelial growth factor and free IGF-I levels were elevated
in  diabetic  patients  with  PDR,  compared  to  nondiabetic
controls. However, because vitreous levels of IGF-I did not
correlate with active PDR status, they concluded that vascular
endothelial  growth  factor  was  directly  involved  with  the
pathogenesis  of  PDR,  whereas  the  precise  role  of  IGF-I
remained to be established.
Serum IGF-I levels have been related to age in the general
population, with low levels in childhood, peak levels during
puberty, and gradually declining levels in adulthood. While
the current study only focused on adult subjects with type 2
diabetes, there was a significant difference in IGF-I levels
according to age. This finding correlates well with that of Tan
and Baxter [26], who showed a decline in serum IGF-I levels
with  increasing  age  in  an  adult-onset  diabetic  population.
Nardelli and colleagues [27] found no correlation between
IGF-I and age in their insulin-using and non-insulin-using
diabetic groups, but did find a negative correlation between
IGF-I and age in their nondiabetic control population. The
association between IGF-I and age in the current study should
not change according to insulin status, because the IGF-I
levels were virtually identical in the insulin-dependent and
non-insulin-dependent diabetic subjects (116.8 µg/l versus
118.2 µg/l).
Many of the subjects in this study, particularly those with
diabetic retinopathy, had concomitant systemic hypertension.
It should be noted that the blood pressure measurements of
these patients were not recorded. Instead, patients were asked
whether  they  had  been  previously  diagnosed  with
hypertension.  Interestingly,  there  was  no  significant
association  between  serum  IGF-I  concentrations  and  the
presence of hypertension (p=0.131). This finding contrasts
previous studies that show that lower levels of serum IGF-I
correlate with systemic hypertension [28–30]. Furthermore,
IGF-I has been implicated in the development of hypertension
through its inotropic and growth-promoting effects on the
heart  and  endothelium  [31].  Possibly  due  to  patient
characteristics  or  small  sample  sizes,  we  did  not  find  an
association  between  serum  IGF-I  concentrations  and
hypertension. It is also possible that an association between
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had collected blood pressure measurements. Further studies
are needed to clarify the pathogenic role IGF-I has in the
development of hypertension.
As the kidney is a major site of IGF-I degradation, it could
be expected that IGF-I levels may be higher in patients with
renal insufficiency [32]. Hyer and colleagues [11] found this
to be true. Interestingly, the current study found no association
between serum creatinine levels or estimated GFR and IGF-I
levels. This result is similar to other studies that found no
association between IGF-I and renal failure [8,10,12]. It is
unclear why these studies were unable to find an association
between IGF-I and renal insufficiency. It is possible that an
association exists, but it is weak.
There were a few limitations to the current study. First,
its  cross-sectional  design  limited  our  ability  to  assess
causality. Second, only one time point was recorded for the
subjects. A longitudinal analysis of these patients, with serial
fundoscopic  examinations  and  blood  testing,  would  be
valuable for determining whether our findings hold true over
time. Furthermore, only serum IGF-I levels were measured.
As mentioned earlier, the serum IGF-I assay we used did not
cross-react with IGF-II, and it minimized the interference
from the high-affinity binding proteins. It thus should have
reflected the true serum IGF-I level. Nonetheless, it might
have been useful to measure IGF-II levels and IGF-binding
proteins to see if there were any associations with the IGF-I
levels or with diabetic retinopathy.
In conclusion, this large cross-sectional study found no
association  between  serum  IGF-I  levels  and  diabetic
retinopathy. Our results call into question whether serum IGF-
I  contributes  to  the  pathogenesis  of  diabetic  retinopathy.
Additional  prospective  studies  are  needed  to  assess  the
potential significance of IGF-I as a risk factor for diabetic
retinopathy, and also to evaluate the effects of suppressing
systemic  or  intraocular  IGF-I  on  the  progression  of
retinopathy.
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